berlin-biotech
(2)
Tom Soloway
Tom Soloway is the Chief Executive Officer of T-knife Therapeutics, a transatlantic biotech developing T-cell receptor (TCR-T) therapies aimed at solid tumors. With more than 25 years across strategy, operations, corporate finance and venture capital, he has helped build and finance a string of life sciences companies including Transcept Pharmaceuticals, Ascendis Pharma and Audentes Therapeutics. He took the helm of T-knife in January 2021, positioning the Berlin- and San Francisco-based company to move its 'supercharged' TCR-T candidates into the clinic while staying lean and capital-efficient.
T-knife Therapeutics
T-knife Therapeutics is a clinical-stage biotech engineering T-cell receptor (TCR-T) therapies to treat solid tumors. Spun out of Berlin's Max Delbrück Center in 2015, it built a proprietary humanized-TCR mouse platform (HuTCR) that grows a full human immune repertoire in mice, letting the company harvest fully human TCRs naturally selected for affinity and specificity. Now dual-based in San Francisco and Berlin, T-knife is advancing 'supercharged' TCR-T candidates - including a PRAME-targeted, CRISPR-armored therapy (TK-6302) entering the clinic - against cancers that have long resisted cell therapy.